Doxorubicin@ Bcl-2 siRNA core@ shell nanoparticles for synergistic anticancer chemotherapy

M Zhou, X Zhang, X Xu, X Chen… - ACS Applied Bio …, 2018 - ACS Publications
Acquired drug resistance in malignant tumors seriously hinders effective chemotherapy
against cancer. The main mechanisms of drug resistance include decreased drug influx …
被引用次数：15 相关文章

Doxorubicin@ Bcl-2 siRNA core@ shell nanoparticles for synergistic anticancer chemotherapy

M Zhou, X Zhang, X Xu, X Chen… - ACS Applied …, 2018 - research.ed.ac.uk
Acquired drug resistance in malignant tumors seriously hinders effective chemotherapy
against cancer. The main mechanisms of drug resistance include decreased drug influx …

[引用][C] Doxorubicin@ Bcl-2 siRNA Core@ Shell nanoparticles for synergistic anticancer chemotherapy

M Zhou, X Zhang, X Xu, X Chen - ACS Applied Bio Materials, 2018 - elibrary.ru

Doxorubicin@ Bcl-2 siRNA Core@ Shell Nanoparticles for Synergistic Anticancer Chemotherapy

M Zhou, X Zhang, X Xu, X Chen… - ACS applied bio …, 2018 - pubmed.ncbi.nlm.nih.gov
Acquired drug resistance in malignant tumors seriously hinders effective chemotherapy
against cancer. The main mechanisms of drug resistance include decreased drug influx …

Doxorubicin@ Bcl-2 siRNA Core@ Shell Nanoparticles for Synergistic Anticancer Chemotherapy.

M Zhou, X Zhang, X Xu, X Chen - ACS Applied bio Materials, 2018 - europepmc.org
Acquired drug resistance in malignant tumors seriously hinders effective chemotherapy
against cancer. The main mechanisms of drug resistance include decreased drug influx …